Lipospheres and pro-nano lipospheres for delivery of poorly water soluble compounds

Chemistry and Physics of Lipids

Volumn 165, Issue 4, 2012, Pages 438-453

  Elgart, Anna ^a   Cherniakov, Irina ^a   Aldouby, Yanir ^a   Domb, Abraham J ^a   Hoffman, Amnon ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Drug delivery; Lipospheres; Ocular drug delivery; Oral drug delivery; Parenteral drug delivery; Pro nano lipospheres; Solid lipid nano particles

Indexed keywords

AMPHOTERICIN B; CYCLOSPORIN; CYCLOSPORIN A; LIPID; PACLITAXEL; PHOSPHOLIPID; TOBRAMYCIN;

CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SCREENING; ELECTRON MICROSCOPY; EMULSION; ENZYME POLYMORPHISM; HYDROPHOBICITY; IN VITRO STUDY; LIPOLYSIS; LIPOSPHERE; NANOENCAPSULATION; PARTICLE SIZE; PRIORITY JOURNAL; PRO NANO LIPOSPHERE;

ANIMALS; DRUG ADMINISTRATION ROUTES; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; NANOSPHERES; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; WATER;

EID: 84860713780     PISSN: 00093084     EISSN: 18732941     Source Type: Journal    
DOI: 10.1016/j.chemphyslip.2012.01.007     Document Type: Conference Paper

References (134)

1. M.R. Aji Alex, A.J. Chacko, S. Jose, and E.B. Souto Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting Eur. J. Pharm. Sci. 42 2011 11 18
2. M.J. Alonso Nanomedicines for overcoming biological barriers Biomed. Pharmacother. 58 2004 168 172
3. G.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 12 1995 413 420
4. S. Amselem Delivery systems for vaccines S.B.H. Cohen, Microparticulate Systems for Drug Delivery 1996 Marcel Dekker New York 149
5. S. Amselem, C.R. Alving, and A.J. Domb Polymeric biodegradable lipospheres as vaccine delivery systems Polym. Adv. Technol. 3 1992 351
6. S. Amselem, A.J. Domb, and C.R. Alving Lipospheres as vaccine carrier systems: effects of size, charge, and phospholipid composition Vaccine Res. 1 1992 383
7. A.A. Attama, and C.C. Muller-Goymann Investigation of surface-modified solid lipid nanocontainers formulated with a heterolipid-templated homolipid Int. J. Pharm. 334 2007 179 189
8. A.A. Attama, S. Reichl, and C.C. Muller-Goymann Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct Int. J. Pharm. 355 2008 307 313
9. J.H. Baker 2nd, J. McKenzie 3rd, S. Beau, G.S. Greer, J. Porterfield, M. Fedor, S. Greenberg, E.G. Daoud, R. Corbisiero, J.R. Bailey, and L. Porterfield Acute evaluation of programmer-guided AV/PV and VV delay optimization comparing an IEGM method and echocardiogram for cardiac resynchronization therapy in heart failure patients and dual-chamber ICD implants J. Cardiovasc. Electrophysiol. 18 2007 185 191
10. D. Balayssac, N. Authier, A. Cayre, and F. Coudore Does inhibition of P-glycoprotein lead to drug-drug interactions? Toxicol. Lett. 156 2005 319 329
11. A. Bargoni, R. Cavalli, O. Caputo, A. Fundaro, M.R. Gasco, and G.P. Zara Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats Pharm. Res. 15 1998 745 750
12. T. Bekerman, J. Golenser, and A. Domb Cyclosporin nanoparticulate lipospheres for oral administration J. Pharm. Sci. 93 2004 1264 1270
13. L.Z. Benet Predicting drug disposition via application of a biopharmaceutics drug disposition classification system Basic Clin. Pharmacol. Toxicol. 106 2010 162 167
14. B. Bittner, A. Guenzi, P. Fullhardt, G. Zuercher, R.C. Gonzalez, and R.J. Mountfield Improvement of the bioavailability of colchicine in rats by co-administration of d-alpha-tocopherol polyethylene glycol 1000 succinate and a polyethoxylated derivative of 12-hydroxy-stearic acid Arzneimittelforschung 52 2002 684 688
15. C. Bocca, O. Caputo, R.B. Cavalli, L. Gabriel, A. Miglietta, and M.R. Gasco Phagocytic uptake of fluorescent stealth and non-stealth solid lipid nanoparticles Int. J. Pharm. 175 1998 185 193
16. H. Bohets, P. Annaert, G. Mannens, L. Van Beijsterveldt, K. Anciaux, P. Verboven, W. Meuldermans, and K. Lavrijsen Strategies for absorption screening in drug discovery and development Curr. Top. Med. Chem. 1 2001 367 383
17. C.L. Bourlais, L. Acar, H. Zia, P.A. Sado, T. Needham, and R. Leverge Ophthalmic drug delivery systems - recent advances Prog. Retin. Eye Res. 17 1998 33 58
18. H. Bunjes Lipid nanoparticles for the delivery of poorly water-soluble drugs J. Pharm. Pharmacol. 62 2010 1637 1645
19. H. Bunjes, M.H. Koch, and K. Westesen Influence of emulsifiers on the crystallization of solid lipid nanoparticles J. Pharm. Sci. 92 2003 1509 1520
20. H. Bunjes, F. Steiniger, and W. Richter Visualizing the structure of triglyceride nanoparticles in different crystal modifications Langmuir 23 2007 4005 4011
21. P.G. Cardiello, T. Samor, D. Burger, R. Hoetelmans, A. Mahanontharit, K. Ruxrungtham, J.M. Lange, D.A. Cooper, and P. Phanuphak Pharmacokinetics of lower doses of saquinavir soft-gel caps (800 and 1200 mg twice daily) boosted with itraconazole in HIV-1-positive patients Antivir. Ther. 8 2003 245 249
22. R. Cavalli, M.R. Gasco, P. Chetoni, S. Burgalassi, and M.F. Saettone Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin Int. J. Pharm. 238 2002 241 245
23. T. Chang, L.Z. Benet, and M.F. Hebert The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers Clin. Pharmacol. Ther. 59 1996 297 303
24. W.N. Charman Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine Int. J. Pharm. 167 1998 155 164
25. J.H. Charuk, P.Y. Wong, and R.A. Reithmeier Differential interaction of human renal P-glycoprotein with various metabolites and analogues of cyclosporin A Am. J. Physiol. 269 1995 F31 F39
26. D.B. Chen, T.Z. Yang, W.L. Lu, and Q. Zhang In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel Chem. Pharm. Bull. (Tokyo) 49 2001 1444 1447
27. N. Chiannilkulchai, N. Ammoury, B. Caillou, J.P. Devissaguet, and P. Couvreur Hepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastasis-bearing mice Cancer Chemother. Pharmacol. 26 1990 122 126
28. A. Chrastina, K.A. Massey, and J.E. Schnitzer Overcoming in vivo barriers to targeted nanodelivery Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 3 2011 421 437
29. P.P. Constantinides Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects Pharm. Res. 12 1995 1561 1572
30. G. Cornaire, J. Woodley, P. Hermann, A. Cloarec, C. Arellano, and G. Houin Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo Int. J. Pharm. 278 2004 119 131
31. R. Cortesi, E. Esposjto, G. Luca, and C. Nastruzzi Production of lipospheres as carriers for bioactive compounds Biomaterials 23 2002 2283 2294
32. A. Dahan, and A. Hoffman Mode of administration-dependent brain uptake of indomethac: sustained systemic input increases brain influx Drug Metab. Dispos. 35 2007 321 324
33. A. Dahan, and A. Hoffman Enhanced gastrointestinal absorption of lipophilic drugs E. Touitou, B.W. Barry, Enhancement in Drug Delivery 2007 CRC Press LLC Boca Raton 111 131
34. S. Das, and A. Chaudhury Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery AAPS PharmSciTech 12 2011 62 76
35. A.A. Date, N. Desai, R. Dixit, and M. Nagarsenker Self-nanoemulsifying drug delivery systems: formulation insights, applications and advances Nanomedicine (Lond.) 5 2010 1595 1616
36. N.M. Davies Biopharmaceutical considerations in topical ocular drug delivery Clin. Exp. Pharmacol. Physiol. 27 2000 558 562
37. M.P. Desai, V. Labhasetwar, G.L. Amidon, and R.J. Levy Gastrointestinal uptake of biodegradable microparticles: effect of particle size Pharm. Res. 13 1996 1838 1845
38. D. Dimitrijevic, A.J. Shaw, and A.T. Florence Effects of some non-ionic surfactants on transepithelial permeability in Caco-2 cells J. Pharm. Pharmacol. 52 2000 157 162
39. J.M. Dintaman, and J.A. Silverman Inhibition of P-glycoprotein by d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS) Pharm. Res. 16 1999 1550 1556
40. A. Domb Lipospheres for controlled delivery of substances S. Benita, Microencapsulation; Methods and Industrial Applications 2nd ed. 2006 Taylor and Francis Boca Raton 297 316
41. A.J. Domb, L. Bergelson, and S. Amselem Lipospheres for controlled delivery of substances Microencapsulation, Methods and Industrial Applications 1996 Marcel Dekker New York p. 377
42. A.J. Domb, A. Marlinsky, M. Maniar, and L. Teomim Insect repellent formulations of N,N-diethyl-m-toluamide (deet) in a liposphere system: efficacy and skin uptake J. Am. Mosq. Control Assoc. 11 1995 29 34
43. B. Drake, C.B. Prater, A.L. Weisenhorn, S.A. Gould, T.R. Albrecht, C.F. Quate, D.S. Cannell, H.G. Hansma, and P.K. Hansma Imaging crystals, polymers, and processes in water with the atomic force microscope Science 243 1989 1586 1589
44. E. Eljarrat-Binstock, and A. Domb Nanoparticles in ocular drug delivery A. Domb, Y. Tabata, M.N.V. Ravi Kumar, S. Farber, Nanoparticles for Pharmaceutical Applications 2007 American Scientific Publishers Stevenson Ranch 367 375
45. D.B. Fenske Structural and motional properties of vesicles as revealed by nuclear magnetic resonance Chem. Phys. Lipids 64 1993 143 162
46. C. Freitas, and R.H. Muller Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase Eur. J. Pharm. Biopharm. 47 1999 125 132
47. A. Fundaro, R. Cavalli, A. Bargoni, D. Vighetto, G.P. Zara, and M.R. Gasco Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats Pharmacol. Res. 42 2000 337 343
48. T. Gershanik, and S. Benita Positively charged self-emulsifying oil formulation for improving oral bioavailability of progesterone Pharm. Dev. Technol. 1 1996 147 157
49. T. Gershanik, and S. Benita Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs Eur. J. Pharm. Biopharm. 50 2000 179 188
50. T. Gershanik, S. Benzeno, and S. Benita Interaction of a self-emulsifying lipid drug delivery system with the everted rat intestinal mucosa as a function of droplet size and surface charge Pharm. Res. 15 1998 863 869
51. T. Gershanik, E. Haltner, C.M. Lehr, and S. Benita Charge-dependent interaction of self-emulsifying oil formulations with Caco-2 cells monolayers: binding, effects on barrier function and cytotoxicity Int. J. Pharm. 211 2000 29 36
52. P. Gershkovich, K.M. Wasan, and C.A. Barta A review of the application of lipid-based systems in systemic, dermal/transdermal, and ocular drug delivery Crit. Rev. Ther. Drug Carrier Syst. 25 2008 545 584
53. S.K. Gupta, R.C. Manfro, S.J. Tomlanovich, J.G. Gambertoglio, M.R. Garovoy, and L.Z. Benet Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration J. Clin. Pharmacol. 30 1990 643 653
54. R.N. Gursoy, and S. Benita Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs Biomed. Pharmacother. 58 2004 173 182
55. O. Harush-Frenkel, Y. Altschuler, and S. Benita The impact of surface charge on nanoparticle performance A. Domb, Y. Tabata, M.N.V. Ravi Kumar, S. Farber, Nanoparticles for Pharmaceutical Applications 2007 American Scientific Publishers Stevenson Ranch 85 102
56. D.J. Hauss, S.E. Fogal, J.V. Ficorilli, C.A. Price, T. Roy, A.A. Jayaraj, and J.J. Keirns Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor J. Pharm. Sci. 87 1998 164 169
57. L. Hu, X. Tang, and F. Cui Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs J. Pharm. Pharmacol. 56 2004 1527 1535
58. A.J. Humberstone, and W.N. Charman Lipid-based vehicles for the oral delivery of poorly water soluble drugs Adv. Drug Deliv. Rev. 25 1997 103 128
59. N. Hussain, V. Jaitley, and A.T. Florence Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics Adv. Drug Deliv. Rev. 50 2001 107 142
60. J.M. Irache, I. Esparza, C. Gamazo, M. Agueros, and S. Espuelas Nanomedicine: novel approaches in human and veterinary therapeutics Vet. Parasitol. 180 2011 47 71
61. V. Jenning, M. Schafer-Korting, and S. Gohla Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties J. Control. Release 66 2000 115 126
62. L. Kagan, and A. Hoffman Selection of drug candidates for gastroretentive dosage forms: pharmacokinetics following continuous intragastric mode of administration in a rat model Eur. J. Pharm. Biopharm. 69 2008 238 246
63. A. Kagayama, S. Tanimoto, J. Fujisaki, A. Kaibara, K. Ohara, K. Iwasaki, Y. Hirano, and T. Hata Oral absorption of FK506 in rats Pharm. Res. 10 1993 1446 1450
64. T. Kino, H. Hatanaka, M. Hashimoto, M. Nishiyama, T. Goto, M. Okuhara, M. Kohsaka, H. Aoki, and H. Imanaka FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics J. Antibiot. (Tokyo) 40 1987 1249 1255
65. K. Kohli, S. Chopra, D. Dhar, S. Arora, and R.K. Khar Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability Drug Discov. Today 15 2010 958 965
66. Y.C. Kuo, and H.H. Chen Entrapment and release of saquinavir using novel cationic solid lipid nanoparticles Int. J. Pharm. 365 2009 206 213
67. A. Larsen, R. Holm, M.L. Pedersen, and A. Mullertz Lipid-based formulations for danazol containing a digestible surfactant, Labrafil M2125CS: in vivo bioavailability and dynamic in vitro lipolysis Pharm. Res. 25 2008 2769 2777
68. H. Lennernas, B. Abrahamsson, E.M. Persson, and L. Knutson Oral drug absorption and the biopharmaceutics classification system J. Drug Del. Sci. Tech. 17 2007 237 244
69. H. Li, X. Zhao, Y. Ma, G. Zhai, L. Li, and H. Lou Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles J. Control. Release 133 2009 238 244
70. L.C. Li, and Y. Tian Zeta potential J. Swarbrick, Encyclopedia of Pharmaceutical Technology 2007 Informa Healthcare New York 4117 4128
71. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 46 2001 3 26
72. X. Liu, Y. Zhang, X. Tang, and H. Zhang Determination of entrapment efficiency and drug phase distribution of submicron emulsions loaded silybin J. Microencapsul. 26 2009 180 186
73. M.H. Maniar, D. Amselem, S. Xie, X. Burch, and R.A.J. Domb Characterization of lipospheres: effect of carrier and phospholipid on the loading of drug into the lipospheres Pharm. Res. 1991 8
74. K. Manjunath, and V. Venkateswarlu Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration J. Drug Target. 14 2006 632 645
75. A.R. Markos, A.A. Wade, M. Walzman, and M. Shahmanesh Self sampling as part of screening for sexually transmitted diseases in clinic attenders. A preliminary study Int. J. STD AIDS 5 1994 284 286
76. W. Mehnert, and K. Mader Solid lipid nanoparticles: production, characterization and applications Adv. Drug Deliv. Rev. 47 2001 165 196
77. R.C. Mehta, L.F. Head, A.M. Hazrati, M. Parr, R.P. Rapp, and P.P. DeLuca Fat emulsion particle-size distribution in total nutrient admixtures Am. J. Hosp. Pharm. 49 1992 2749 2755
78. P.R. Mishra, L. Al Shaal, R.H. Muller, and C.M. Keck Production and characterization of Hesperetin nanosuspensions for dermal delivery Int. J. Pharm. 371 2009 182 189
79. S.M. Moghimi, A.C. Hunter, and J.C. Murray Long-circulating and target-specific nanoparticles: theory to practice Pharmacol. Rev. 53 2001 283 318
80. S. Morel, M.R. Gasco, and R. Cavalli Incorporation in lipospheres of [D-Trp-6]Lhrh (Vol 105 Pg R1, 1994) Int. J. Pharm. 119 1995 126
81. R.J. Mountfield, S. Senepin, M. Schleimer, I. Walter, and B. Bittner Potential inhibitory effects of formulation ingredients on intestinal cytochrome P450 Int. J. Pharm. 211 2000 89 92
82. M. Muchow, P. Maincent, and R.H. Muller Lipid nanoparticles with a solid matrix (SLN, NLC LDC) for oral drug delivery Drug Dev. Ind. Pharm. 34 2008 1394 1405
83. E.A. Mueller, J.M. Kovarik, J.B. van Bree, J. Grevel, P.W. Lucker, and K. Kutz Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation Pharm. Res. 11 1994 151 155
84. S. Mukherjee, S. Ray, and R.S. Thakur Solid lipid nanoparticles: a modern formulation approach in drug delivery system Indian J. Pharm. Sci. 71 2009 349 358
85. R.H. Muller, C. Jacobs, and O. Kayser Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future Adv. Drug Deliv. Rev. 47 2001 3 19
86. R.H. Muller, and C.M. Keck Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles J. Biotechnol. 113 2004 151 170
87. R.H. Muller, K. Mader, and S. Gohla Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art Eur. J. Pharm. Biopharm. 50 2000 161 177
88. T. Nassar, S. Attili-Qadri, O. Harush-Frenkel, S. Farber, S. Lecht, P. Lazarovici, and S. Benita High plasma levels and effective lymphatic uptake of docetaxel in an orally available nanotransporter formulation Cancer Res. 71 2011 3018 3028
89. F.S. Nielsen, K.B. Petersen, and A. Mullertz Bioavailability of probucol from lipid and surfactant based formulations in minipigs: influence of droplet size and dietary state Eur. J. Pharm. Biopharm. 69 2008 553 562
90. D. Patel, and K.K. Sawant Self micro-emulsifying drug delivery system: formulation development and biopharmaceutical evaluation of lipophilic drugs Curr. Drug Deliv. 6 2009 419 424
91. PDR, 2012.
92. D. Peer, J.M. Karp, S. Hong, O.C. Farokhzad, R. Margalit, and R. Langer Nanocarriers as an emerging platform for cancer therapy Nat. Nanotechnol. 2 2007 751 760
93. C.J. Porter, and W.N. Charman In vitro assessment of oral lipid based formulations Adv. Drug Deliv. Rev. 50 Suppl. 1 2001 S127 S147
94. C.J. Porter, A.M. Kaukonen, B.J. Boyd, G.A. Edwards, and W.N. Charman Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation Pharm. Res. 21 2004 1405 1412
95. C.J. Porter, N.L. Trevaskis, and W.N. Charman Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs Nat. Rev. Drug Discov. 6 2007 231 248
96. C.W. Pouton Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems Eur. J. Pharm. Sci. 11 Suppl. 2 2000 S93 S98
97. C.W. Pouton Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system Eur. J. Pharm. Sci. 29 2006 278 287
98. C.W. Pouton, and C.J. Porter Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies Adv. Drug Deliv. Rev. 60 2008 625 637
99. J.W. Puntis, K.M. Wilkins, P.A. Ball, D.I. Rushton, and I.W. Booth Hazards of parenteral treatment: do particles count? Arch Dis Child 67 1992 1475 1477
100. X. Ren, X. Mao, L. Si, L. Cao, H. Xiong, J. Qiu, A.D. Schimmer, and G. Li Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration Eur. J. Pharm. Biopharm. 70 2008 279 288
101. S.K. Sahoo, F. Dilnawaz, and S. Krishnakumar Nanotechnology in ocular drug delivery Drug Discov. Today 13 2008 144 151
102. K.K. Sawnt, and S.S. Dodiya Recent advances and patents on solid lipid nanoparticles Recent Pat. Drug Deliv. Formul. 2 2008 120 135
103. C. Schwarz, and W. Mehnert Solid lipid nanoparticles (SLN) for controlled drug delivery II. Drug incorporation and physicochemical characterization J. Microencapsul. 16 1999 205 213
104. A. Seyfoddin, J. Shaw, and R. Al-Kassas Solid lipid nanoparticles for ocular drug delivery Drug Deliv. 17 2010 467 489
105. P. Shahgaldian, L. Quattrocchi, J. Gualbert, A.W. Coleman, and P. Goreloff AFM imaging of calixarene based solid lipid nanoparticles in gel matrices Eur. J. Pharm. Biopharm. 55 2003 107 113
106. Shapira, A.; Livney, Y.D.; Broxterman, H.J.; Assaraf, Y.G. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist. Updat. 14, 150-163.
107. R. Shapiro Tacrolimus in solid organ transplantation: an update Transplant Proc. 31 1999 2203 2205
108. M. Shimomura, S. Masuda, H. Saito, S. Sakamoto, S. Uemoto, K. Tanaka, and K. Inui Roles of the jejunum and ileum in the first-pass effect as absorptive barriers for orally administered tacrolimus J. Surg. Res. 103 2002 215 222
109. D. Shukla, S. Chakraborty, S. Singh, and B. Mishra Lipid-based oral multiparticulate formulations - advantages, technological advances and industrial applications Expert Opin. Drug Deliv. 8 2011 207 224
110. K. Sigfridsson, A.J. Lundqvist, and M. Strimfors Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development Drug Dev. Ind. Pharm. 35 2009 1479 1486
111. E.B. Souto, W. Mehnert, and R.H. Muller Polymorphic behaviour of Compritol888 ATO as bulk lipid and as SLN and NLC J. Microencapsul. 23 2006 417 433
112. E.B. Souto, and R.H. Muller Lipid nanoparticles (SLN and NLC) for drug delivery A. Domb, Y. Tabata, M.N.V. Ravi Kumar, S. Farber, Nanoparticles for Pharmaceutical Applications 2007 American Scientific Publishers Stevenson Ranch 103 122
113. C.M. Spencer, K.L. Goa, and J.C. Gillis Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation Drugs 54 1997 925 975
114. R.G. Srickley Currently marketed oral lipid based dosage forms: drug products and excipients D.J. Hauss, Oral Lipid-Based Formulations; Enhancing the Bioavailability of Poorly Water-Soluble Drugs 2007 Informa New York 1 33
115. S. Tamilvanan, and S. Benita The potential of lipid emulsion for ocular delivery of lipophilic drugs Eur. J. Pharm. Biopharm. 58 2004 357 368
116. S. Tamura, A. Ohike, R. Ibuki, G.L. Amidon, and S. Yamashita Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats J. Pharm. Sci. 91 2002 719 729
117. B. Tang, G. Cheng, J.C. Gu, and C.H. Xu Development of solid self-emulsifying drug delivery systems: preparation techniques and dosage forms Drug Discov. Today 13 2008 606 612
118. B.D. Tarr, and S.H. Yalkowsky Enhanced intestinal absorption of cyclosporine in rats through the reduction of emulsion droplet size Pharm. Res. 6 1989 40 43
119. A.J. ten Tije, J. Verweij, W.J. Loos, and A. Sparreboom Pharmacological effects of formulation vehicles: implications for cancer chemotherapy Clin. Pharmacokinet. 42 2003 665 685
120. K. Thomas, C. Koelwel, U. Machei, L. Farber, and A. Gopferich Three generations of cyclosporine a formulations: an in vitro comparison Drug Dev. Ind. Pharm. 31 2005 357 366
121. N.L. Trevaskis, W.N. Charman, and C.J. Porter Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update Adv. Drug Deliv. Rev. 60 2008 702 716
122. M.J. Tsai, Y.B. Huang, P.C. Wu, Y.S. Fu, Y.R. Kao, J.Y. Fang, and Y.H. Tsai Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations J. Pharm. Sci. 100 2010 547 557
123. M. Uner, S.A. Wissing, G. Yener, and R.H. Muller Influence of surfactants on the physical stability of solid lipid nanoparticle (SLN) formulations Pharmazie 59 2004 331 332
124. J. Varshosaz, M. Minayian, and E. Moazen Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles J. Liposome Res. 20 2009 115 123
125. Washington, C.; 2011. Zeta potential for pharmaceutical formulations.
126. S.A. Wissing, O. Kayser, and R.H. Muller Solid lipid nanoparticles for parenteral drug delivery Adv. Drug Deliv. Rev. 56 2004 1257 1272
127. H.L. Wong, R. Bendayan, A.M. Rauth, Y. Li, and X.Y. Wu Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles Adv. Drug Deliv. Rev. 59 2007 491 504
128. S. Yang, J. Zhu, Y. Lu, B. Liang, and C. Yang Body distribution of camptothecin solid lipid nanoparticles after oral administration Pharm. Res. 16 1999 751 757
129. L. Yu, A. Bridgers, J. Polli, A. Vickers, S. Long, A. Roy, R. Winnike, and M. Coffin Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability Pharm. Res. 16 1999 1812 1817
130. G.P. Zara, A. Bargoni, R. Cavalli, A. Fundaro, D. Vighetto, and M.R. Gasco Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats J. Pharm. Sci. 91 2002 1324 1333
131. G.P. Zara, R. Cavalli, A. Bargoni, A. Fundaro, D. Vighetto, and M.R. Gasco Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues J. Drug Target. 10 2002 327 335
132. Z. Zhang, F. Gao, H. Bu, J. Xiao, and Y. Li Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats Nanomedicine 2011
133. A. zur Muhlen, C. Schwarz, and W. Mehnert Solid lipid nanoparticles (SLN) for controlled drug delivery - drug release and release mechanism Eur. J. Pharm. Biopharm. 45 1998 149 155
134. A. zur Muhlen, E. zur Muhlen, H. Niehus, and W. Mehnert Atomic force microscopy studies of solid lipid nanoparticles Pharm. Res. 13 1996 1411 1416